Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Andreas Hochhaus, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Richard A. Larson, MD, Lilia Taningco, MSc, Weiping Deng, Hans D Menssen, MD PhD, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 2781.

https://doi.org/10.1182/blood.V126.23.2781.2781

Published: 2015

Journal Articles

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Richard A. Larson, Dong-Wook Kim, MD PhD, Surapol Issaragrilsil, MD, Philipp le Coutre, MD, Pedro Enrique Dorlhiac Llacer, Gabriel Etienne, MD PhD, Richard E. Clark, MD, Ian Flinn, Hirohisa Nakamae, Andreas Hochhaus, MD, Giuseppe Saglio, MD, Hagop M. Kantarjian, Breanne Donohue, PharmD, Weiping Deng, PhD, Hans D. Menssen, MD PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4541.

https://doi.org/10.1182/blood.V124.21.4541.4541

Published: 2014

Journal Articles

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Xiaojun Huang, Jianxiang Wang, MD, Michele Baccarani, MD, Svetlana Jevtic, Christine-Elke Ortmann, Ye Yuan, Hans D. Menssen, MD, PhD, Giuseppe Saglio, Zhi-Xiang Shen, MD

Blood (2013) 122 (21): 1497.

https://doi.org/10.1182/blood.V122.21.1497.1497

Published: 2013

Journal Articles

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, MD, Timothy P. Hughes, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Hirohisa Nakamae, MD, PhD, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, Gabriel Etienne, MD, PHD, Ian Flinn, MD, PhD, Jeffrey H. Lipton, MD, PhD, Ricardo Pasquini, MD, PhD, Beatriz Moiraghi, MD, Charisse Kemp, Xiaolin Fan, PhD, Hans D. Menssen, MD, PhD, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2013) 122 (21): 92.

https://doi.org/10.1182/blood.V122.21.92.92

Published: 2013

NARROW

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Email alerts

ASH Publications

American Society of Hematology

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only